• 1
    World Cancer Research Fund. Food, nutrition and the prevention of cancer: a global perspective. 1997. Washington, DC: American Institute for Cancer Research.
  • 2
    Ferrini RL, Barrett-Connor E. Caffeine intake and endogenous sex steroid levels in postmenopausal women. The Rancho Bernardo Study. Am J Epidemiol 1996; 144: 6424.
  • 3
    Nagata C, Kabuto M, Shimizu H. Association of coffee, green tea, and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women. Nutr Cancer 1998; 30: 214.
  • 4
    Pozner J, Papatestas AE, Fagerstrom R, Schwartz I, Saevitz J, Feinberg M, Aufses AHJr. Association of tumor differentiation with caffeine and coffee intake in women with breast cancer. Surgery 1986; 100: 4828.
  • 5
    Timson J. Effect of theobromine, theophylline and caffeine on the mitosis of human lymphocytes. Mutat Res 1972; 15: 197201.
  • 6
    Le MG. Coffee consumption, benign breast disease, and breast cancer. Am J Epidemiol 1985; 122: 721.
  • 7
    Mannisto S, Pietinen P, Virtanen M, Kataja V, Uusitupa M. Diet and the risk of breast cancer in a case-control study: does the threat of disease have an influence on recall bias? J Clin Epidemiol 1999; 52: 42939.
  • 8
    Michels KB, Holmberg L, Bergkvist L, Wolk A. Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women. Ann Epidemiol 2002; 12: 216.
  • 9
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 26571.
  • 10
    Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94: 17739.
  • 11
    Tavani A, Pregnolato A, La Vecchia C, Favero A, Franceschi S. Coffee consumption and the risk of breast cancer. Eur J Cancer Prev 1998; 7: 7782.
  • 12
    Ewertz M. Breast cancer in Denmark. Incidence, risk factors, and characteristics of survival. Acta Oncol 1993; 32: 595615.
  • 13
    Lubin F, Ron E, Wax Y, Modan B. Coffee and methylxanthines and breast cancer: a case-control study. J Natl Cancer Inst 1985; 74: 56973.
  • 14
    Franceschi S, Favero A, La Vecchia C, Negri E, Dal Maso L, Salvini S, Decarli A, Giacosa A. Influence of food groups and food diversity on breast cancer risk in Italy. Int J Cancer 1995; 63: 7859.
  • 15
    Hunter DJ, Manson JE, Stampfer MJ, Colditz G, Rosner B. A prospective study of caffeine, coffee, tea, and breast cancer. Am J Epidemiol 1992; 136: 10001 (Abstract).
  • 16
    Vatten LJ, Solvoll K, Loken EB. Coffee consumption and the risk of breast cancer. A prospective study of 14,593 Norwegian women. Br J Cancer 1990; 62: 26770.
  • 17
    Snowdon DA, Phillips RL. Coffee consumption and risk of fatal cancers. Am J Public Health 1984; 74: 8203.
  • 18
    Jacobsen BK, Bjelke E, Kvale G, Heuch I. Coffee drinking, mortality, and cancer incidence: results from a Norwegian prospective study. J Natl Cancer Inst 1986; 76: 82331.
  • 19
    Graham S, Zielezny M, Marshall J, Priore R, Freudenheim J, Brasure J, Haughey B, Nasca P, Zdeb M. Diet in the epidemiology of postmenopausal breast cancer in the New York State Cohort. Am J Epidemiol 1992; 136: 132737.
  • 20
    Folsom AR, McKenzie DR, Bisgard KM, Kushi LH, Sellers TA. No association between caffeine intake and postmenopausal breast cancer incidence in the Iowa Women's Health Study. Am J Epidemiol 1993; 138: 3803.
  • 21
    Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, Shibuya D, Tsuji I. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 116: 1504.
  • 22
    Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97: 293300.
  • 23
    Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984; 259: 48405.
  • 24
    Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992; 84: 6348.
  • 25
    Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol 1996; 150 ( Suppl): S25965.
  • 26
    Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998; 11: 65965.
  • 27
    Fowke JH, Qi D, Bradlow HL, Shu XO, Gao YT, Cheng JR, Jin F, Zheng W. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 2003; 68: 6572.
  • 28
    Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998; 27: 2949.
  • 29
    Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6: 5059.
  • 30
    Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11: 63540.
  • 31
    Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78: 12505.
  • 32
    Cauley JA, Zmuda JM, Klug T, Ljung BM, Cummings SR, Kuller LH. Estrogen metabolites and breast cancer: a prospective study. Era of Hope Department of Defense Breast Cancer Research Program Meeting 2000; II: 471.
  • 33
    Narod SA. Hormonal prevention of hereditary breast cancer. Ann NY Acad Sci 2001; 952: 3643.
  • 34
    Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 14759.
  • 35
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 161622.
  • 36
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 160915.
  • 37
    Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 187681.
  • 38
    Kotsopoulos J, Narod S. Towards a dietary prevention of hereditary breast cancer. Cancer Causes Control 2005; 16: 12538.
  • 39
    Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. IARC Sci Publ 1999; 148: 17395.
  • 40
    Lord RS, Bongiovanni B, Bralley JA. Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev 2002; 7: 11229.
  • 41
    Klatsky A, Friedman G, Siegelaub A. Alcohol and tobacco: relations and possible interactions in health and disease. In: AvogaroP, SirtoriC, TremoliE, eds. Metabolic effects of alcohol. The Netherlands: North-Holland Biomedical Press, 1979; 14354.
  • 42
    Schreiber GB, Robins M, Maffeo CE, Masters MN, Bond AP, Morganstein D. Confounders contributing to the reported associations of coffee or caffeine with disease. Prev Med 1988; 17: 295309.
  • 43
    Ghadirian P, Lubinski J, Lynch H, Neuhausen SL, Weber B, Isaacs C, Baruch RG, Randall S, Ainsworth P, Freidman E, Horsman D, Tonin P, et al. Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer 2004; 110: 4136.
  • 44
    Hong CC, Tang BK, Hammond GL, Tritchler D, Yaffe M, Boyd NF. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res 2004; 6: R35265.
  • 45
    Jernstrom H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA. Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. Carcinogenesis 2003; 24: 9911005.
  • 46
    Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50(5 Pt 1): 50819.
  • 47
    Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. Phytochemicals as modulators of cancer risk. Adv Exp Med Biol 1999; 472: 20721.
  • 48
    Mazur W. Phytoestrogen content in foods. Baillieres Clin Endocrinol Metab 1998; 12: 72942.
  • 49
    Horn-Ross PL, Lee M, John EM, Koo J. Sources of phytoestrogen exposure among non-Asian women in California, USA. Cancer Causes Control 2000; 11: 299302.
  • 50
    Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res 2004; 6: 11927.
  • 51
    Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 2004; 91: 51331.